For adult periodontitis. ANDA 65182, held by Epic Pharma LLC. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 65182 (Doxycycline Hyclate), held by Epic Pharma LLC, was first approved by FDA on May 13, 2005, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Doxycycline hyclate tablets, USP are indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture susceptibility information is available, they should be considered in selecting or modifying antibacterial therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 13, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 20MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Mar 31, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 13, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters